Usage of Vinflunine i.v. (JAVLOR) for the Treatment of Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium in Adult Patients After Failure of a Cisplatinum-containing Therapy

Trial Profile

Usage of Vinflunine i.v. (JAVLOR) for the Treatment of Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium in Adult Patients After Failure of a Cisplatinum-containing Therapy

Completed
Phase of Trial: Phase IV

Latest Information Update: 02 Jun 2015

At a glance

  • Drugs Vinflunine (Primary)
  • Indications Urogenital cancer
  • Focus Adverse reactions
  • Acronyms JONAS-1
  • Sponsors Pierre Fabre
  • Most Recent Events

    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 11 Dec 2013 Status changed from active, no longer recruiting to recruiting as reported by German Clinical Trials Register.
    • 29 Jun 2012 Planned end date changed from 1 Jun 2012 to 1 Oct 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top